Patents by Inventor Hideki Kubota

Hideki Kubota has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8314240
    Abstract: [Object] A compound which is useful as an EP1 receptor antagonist is provided. [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: November 20, 2012
    Assignee: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Issei Tsukamoto, Kazunori Kamijo, Koji Kato, Yuta Fukuda, Hidenori Azami
  • Publication number: 20120220609
    Abstract: The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1): [wherein, R1: formula (1A): [wherein, R4 and R5: H, halogen, or alkyl; R6: H, halogen, alkyl, or the like; R7: substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group ?: oxo, hydroxy, amino, or the like; ring Q1: a monocyclic heterocyclic group; ring Q2: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; ring Q3: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; X: a single bond, methylene, ethylene, or the like]; R2: alkyl, or methylsulfanyl; and R3: H, or methyl], or the like.
    Type: Application
    Filed: October 20, 2010
    Publication date: August 30, 2012
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takeshi Kuribayashi, Hideki Kubota, Naoki Tanaka, Takeshi Fukuda, Takashi Tsuji, Riki Goto
  • Patent number: 8114886
    Abstract: The present invention relates to a novel compound having an effect of inhibiting production/secretion of ?-amyloid protein. The present invention provides a compound represented by the general formula (1): or a salt thereof, or a solvate of the compound or the salt; and a medicament comprising thereof.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: February 14, 2012
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Satoru Miyauchi, Hideki Kubota, Kayoko Motoki, Masayuki Ito
  • Publication number: 20110319385
    Abstract: [Problem] Provided is a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like. [Means for Solution] The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibiting action, thereby completing the present invention. The imidazoquinoxaline compound or the triazoloquinoxaline compound of the present invention has a PDE9-inhibiting action and can be used as an agent for preventing and/or treating storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.
    Type: Application
    Filed: March 4, 2010
    Publication date: December 29, 2011
    Applicant: Astellas Pharma Inc.
    Inventors: Hiroyuki Kaizawa, Mari Sugita, Hidenori Azami, Ryushi Seo, Takaho Nomura, Satoshi Yamamoto, Hirofumi Yamamoto, Kazuyuki Tsuchiya, Hideki Kubota, Kazunori Kamijo
  • Publication number: 20110201616
    Abstract: [Object] A compound which is useful as an EP1 receptor antagonist is provided. [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.
    Type: Application
    Filed: June 22, 2009
    Publication date: August 18, 2011
    Applicant: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Issei Tsukamoto, Kazunori Kamijo, Koji Kato, Yuta Fukuda, Hidenori Azami
  • Patent number: 7973078
    Abstract: A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular a lower urinary tract symptom. It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: July 5, 2011
    Assignee: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Susumu Toda, Issei Tsukamoto, Yuta Fukuda, Ryutaro Wakayama, Kazuki Ono, Toru Watanabe, Hidenori Azami
  • Publication number: 20110112103
    Abstract: The present invention provides compounds which promote erythropoietin production.
    Type: Application
    Filed: April 21, 2009
    Publication date: May 12, 2011
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takeshi Kuribayashi, Hideki Kubota, Takeshi Fukuda, Rieko Takano, Takashi Tsuji, Koji Sasaki, Naoki Tanaka
  • Patent number: 7932271
    Abstract: Provided is a compound capable of inhibiting production or secretion of ? amyloid protein. A compound represented by the following formula (1): (wherein, R1 represents a heterocyclic group which may have a substituent, R2 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R3 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R4 represents a hydrogen atom or a C1-6 alkyl group, and X represents —S—, —SO— or —SO2—); an N-oxide or S-oxide thereof; a salt thereof; or a solvate thereof; and a medicament containing any of them.
    Type: Grant
    Filed: June 29, 2004
    Date of Patent: April 26, 2011
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Hideki Kubota, Takanori Yasukouchi, Satoru Miyauchi, Kayoko Motoki, Masanori Saito, Hitoshi Iimori
  • Publication number: 20100168136
    Abstract: A compound having activity to inhibit production and/or secretion of ?-amyloid protein, and is useful for prevention and/or treatment of various diseases associated with abnormal production and/or secretion of ?-amyloid protein, the compound represented by the general formula (I): [wherein, R1 represents a C1-C6 alkyl group which may have 1 to 6 halogen atoms as substituent groups, a C2-C6 alkenyl group which may have 1 to 6 halogen atoms as substituent groups, or a C3-C7 cycloalkyl group which may have 1 to 6 halogen atoms as substituent groups; R2 represents a 6-membered nitrogen-containing monocyclic aromatic heterocyclic group having 1 to 3 substituent groups, or a 9- or 10-membered nitrogen-containing bicyclic heterocyclic group having 1 to 4 substituent groups; Z1, Z2 and Z3 each independently represent a hydrogen atom, a halogen atom or a cyano group; and n represents 0, 1 or 2], salts thereof, or solvates thereof.
    Type: Application
    Filed: March 11, 2010
    Publication date: July 1, 2010
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hitoshi Iimori, Hideki Kubota, Satoru Miyauchi, Kayoko Motoki
  • Publication number: 20090312328
    Abstract: [Object] A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom. [Means for Solution] It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.
    Type: Application
    Filed: August 9, 2007
    Publication date: December 17, 2009
    Applicant: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Susumu Toda, Issei Tsukamoto, Yuta Fukuda, Ryutaro Wakayama, Kazuki Ono, Toru Watanabe, Hidenori Azami
  • Publication number: 20090149439
    Abstract: The present invention relates to a novel compound having an effect of inhibiting production/secretion of ?-amyloid protein. The present invention provides a compound represented by the general formula (1): or a salt thereof, or a solvate of the compound or the salt; and a medicament comprising thereof.
    Type: Application
    Filed: April 7, 2006
    Publication date: June 11, 2009
    Applicant: Daiichi Sankyo Company Limited
    Inventors: Satoru Miyauchi, Hideki Kubota, Kayoko Motoki, Masayuki Ito
  • Publication number: 20080227785
    Abstract: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.
    Type: Application
    Filed: February 6, 2008
    Publication date: September 18, 2008
    Applicant: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Takeshi Suzuki, Masanori Miura, Eiichi Nakai, Kiyoshi Yahiro, Akira Miyake, Shinobu Mochizuki, Kazuhiro Nakatou
  • Patent number: 7399775
    Abstract: Provided are novel compounds having an inhibitory activity against production or secretion of ?-amyloid protein. They embrace compounds represented by the following formula (1): and capable of being replaced with a variety of substituents; and salts thereof, and solvates of any one of them.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: July 15, 2008
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Takanori Yasukouchi, Masayuki Ito, Hideki Kubota, Satoru Miyauchi, Masanori Saito
  • Patent number: 7375222
    Abstract: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: May 20, 2008
    Assignee: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Takeshi Suzuki, Masanori Miura, Eiichi Nakai, Kiyoshi Yahiro, Akira Miyake, Shinobu Mochizuki, Kazuhiro Nakatou
  • Publication number: 20080108600
    Abstract: The present invention provides a genus of polycyclic pyridines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.
    Type: Application
    Filed: April 13, 2005
    Publication date: May 8, 2008
    Applicants: Icagen, Inc., Astellas Parma Inc.
    Inventors: Xiaodong Wang, Kerry L. Spear, Alan B. Fulp, Darrick Seconi, Takeshi Suzuki, Takahiro Ishii, Ayako Moritomo, Hideki Kubota, Jun-ichi Kazami
  • Patent number: 7361658
    Abstract: 2-Acylaminothiazole derivatives or salts thereof which have a platelet increasing activity based on an excellent human c-mpl-Ba/F3 cell growth function and a function of accelerating formation of megakaryocytic colonies and which are useful for treating thrombocytopenia are provided.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: April 22, 2008
    Assignee: Astellas Pharma Inc.
    Inventors: Keizo Sugasawa, Yuji Koga, Kazuyoshi Obitsu, Takao Okuda, Koichiro Harada, Hideki Kubota, Fukushi Hirayama, Masaki Abe, Ken-ichi Suzuki
  • Publication number: 20070293495
    Abstract: Provided are novel compounds having an inhibitory activity against production or secretion of ?-amyloid protein. They embrace compounds represented by the following formula (1): and capable of being replaced with a variety of substituents; and salts thereof, and solvates of any one of them.
    Type: Application
    Filed: July 27, 2007
    Publication date: December 20, 2007
    Applicant: DAIICHI PHARMACEUTICAL CO., LTD.
    Inventors: Takanori YASUKOUCHI, Masayuki Ito, Hideki Kubota, Satoru Miyauchi, Masanori Saito
  • Publication number: 20060241302
    Abstract: Provided is a compound capable of inhibiting production or secretion of ? amyloid protein. A compound represented by the following formula (1): (wherein, R1 represents a heterocyclic group which may have a substituent, R2 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R3 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R4 represents a hydrogen atom or a C1-6 alkyl group, and X represents —S—, —SO— or —SO2—); an N-oxide or S-oxide thereof; a salt thereof; or a solvate thereof; and a medicament containing any of them.
    Type: Application
    Filed: June 29, 2004
    Publication date: October 26, 2006
    Inventors: Hideki Kubota, Takanori Yasukouchi, Satoru Miyauchi, Kayoko Motoki, Masanori Saito, Hitoshi Iimori
  • Publication number: 20060194844
    Abstract: 2-Acylaminothiazole derivatives or salts thereof which have a platelet increasing activity based on an excellent human c-mpl-Ba/F3 cell growth function and a function of accelerating formation of megakaryocytic colonies and which are useful for treating thrombocytopenia are provided.
    Type: Application
    Filed: July 15, 2004
    Publication date: August 31, 2006
    Inventors: Keizo Sugasawa, Yuji Koga, Kazuyoshi Obitsu, Takao Okuda, Koichiro Harada, Hideki Kubota, Fukushi Hirayama, Masaki Abe, Ken-ichi Suzuki
  • Patent number: D551167
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: September 18, 2007
    Assignee: Matsushita Electric Industrial Co., Ltd.
    Inventors: Hideki Kubota, Tsuyoshi Konishi